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Impact of Aminoglycoside Cycling in Six Tertiary Intensive Care Units: 
Prospective Longitudinal Interventional Study
Aim To determine the effect of aminoglycoside cycling in six tertiary 
intensive care units (ICU) on the rates of sepsis, aminoglycoside resis-
tance patterns, antibiotic consumption, and costs.
Methods This was a prospective longitudinal interventional study that 
measured the effect of change from first-line gentamicin usage (Febru-
ary 2002-February 2003) to amikacin usage (February 2003-February 
2004) on the aminoglycoside resistance patterns, number of patients 
with gram-negative bacteremia, consumption of antibiotics, and the 
cost of antimicrobial drugs in 6 tertiary care ICUs in Zagreb, Croatia.
Results The change from first-line gentamicin to amikacin usage led 
to a decrease in the overall gentamicin resistance of gram-negative bac-
teria (GNB) from 42% to 26% (P<0.001; z-test of proportions) and 
netilmicin resistance from 33% to 20% (P<0.001), but amikacin resis-
tance did not change significantly (P = 0.462), except for Acinetobacter 
baumanni (P = 0.014). Sepsis rate in ICUs was reduced from 3.6% to 
2.2% (P<0.001; χ2 test), with a decline in the number of nosocomial 
bloodstream infections from 55/100 patient-days to 26/100 patient-
days (P = 0.001, χ2 test). Furthermore, amikacin use led to a 16% de-
crease in the overall antibiotic consumption and € 0.1/patient/d cost 
reduction.
Conclusion Exclusive use of amikacin significantly reduced the resis-
tance of GNB isolates to gentamicin and netilmicin, the number of 
GNB nosocomial bacteremias, and the cost of total antibiotic usage 
in ICUs.
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Despite the introduction of newer, less toxic 
antimicrobial agents, aminoglycosides contin-
ue to have a role in the treatment of serious 
gram-negative bacillary infections. Gentami-
cin, because of its low cost, remains the ami-
noglycoside of choice in hospitals, with low 
levels of resistance among Enterobacteriaceae 
and Pseudomonas aeruginosa (1). Most gram-
negative bacteria (GNB) isolated from pa-
tients in intensive care units (ICU) have be-
come more resistant to gentamicin (2) and 
ICU patients are more likely to have anti-
microbial-resistant organisms than other pa-
tients or outpatients (3).
Aminoglycoside resistance is mediated 
through three key mechanisms: a ribosom-
al mutation, reduced transport into the cell, 
and activity of plasmid-mediated aminoglyco-
side-modifying enzymes (4,5). These enzymes 
include three acetyltransferases, four adenyl-
transferases, and five phosphotransferases (5). 
Aminoglycoside-modifying enzymes are sub-
strate-specific. Gentamicin and tobramycin 
are susceptible to at least five enzymes and the 
result is considerable cross-resistance between 
these two agents. Netilmicin is susceptible 
to four modifying enzymes, while amikacin 
is susceptible to aminoglycoside 6’-N-acet-
yltransferase, and is therefore useful against 
gentamicin-resistant GNB (6). No signifi-
cant increase in the resistance to amikacin has 
been noticed during the past ten years, even 
with extensive and exclusive use (7-9). How-
ever, frequent use of amikacin usually results 
in a decreased resistance to other aminoglyco-
sides (10).
Several discrete strategies have been sug-
gested to prevent or reduce microbial resis-
tance to antimicrobials, including optimal use 
of agents, control, removal or restriction of 
antimicrobials, use of antimicrobials in com-
bination, and rotation or cyclic use of antimi-
crobials (11). The latter strategy is attractive 
because it periodically removes certain class-
es or specific agents that could induce or se-
lect resistance from the institutional environ-
ment (12). The cyclic exposure prevents the 
development of resistance by a growth disad-
vantage of microorganisms when the selective 
antibiotic pressure is withdrawn and by elim-
inating the resistant microorganisms by dif-
ferent antibiotics (13). Studies showed that 
resistance to gentamicin was significantly re-
duced when amikacin was used (14), but it re-
appeared in the first gentamicin recycle. The 
second introduction of amikacin led to a de-
creased resistance to gentamicin, but the sec-
ond introduction of gentamicin did not lead 
to reappearance of resistance (11). Trials that 
monitor the resistance are required to de-
sign optimal protocols and provide clinical-
ly meaningful results (15). However, the ef-
fect of empirical amikacin therapy on ICU 
patients with GNB in blood cultures has not 
been so far shown. Decreasing the number 
of GNB infections has both clinical and eco-
nomical significance.
The aim of this study was to evaluate pro-
spectively the effect of intensive amikacin us-
age on the aminoglycoside resistance patterns, 
number of gram-negative isolates and gram-
negative bacteremias, consumption of antibi-
otics, and the cost of antimicrobial treatment 
in ICUs.
Methods
Setting
Zagreb University Hospital Center is the ma-
jor hospital in Zagreb, Croatia, serving a pop-
ulation of 1 million. The study was conduct-
ed in 6 tertiary care ICUs at the Departments 
of Internal Medicine, Surgery, Cardiac Sur-
gery, Urology, Neurology, and Neurosurgery, 
respectively. These ICUs have 43 beds and 
serve approximately 5000 patients per year. 
They are placed in different parts of the same 
building. The care in each ICU is delivered by 
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a team of attending physicians, residents, and 
nurse practitioners. Hospital infection con-
trol includes the isolation of the patient colo-
nized with methicillin-resistant Staphylococ-
cus aureus, vancomycin-resistant Enterococci, 
Enterobacteriaceae producing extended-spec-
trum beta-lactamases, or any multiple resistant 
GNB in an individual room, whenever possi-
ble. Also, alcohol handrub dispensers are avail-
able and standard procedures of cleaning and 
disinfection of surfaces and equipment and 
hand hygiene are used.
Aminoglycoside cycling intervention
In the first year of the study period (Febru-
ary 28, 2002, to February 28, 2003), genta-
micin was the first-line aminoglycoside used 
(gentamicin period) in both the combination 
therapy and monotherapy. At that time, ami-
kacin was reserved for infections resistant or 
unresponsive to gentamicin. Other amino-
glycosides have not been used. On February 
28, 2003, amikacin was introduced as the sole 
aminoglycoside and was applied until Febru-
ary 29, 2004 (amikacin period). During one 
year, gentamicin was not used in the ICUs. 
The protocol was approved by the Hospital 
Ethics Committee.
Microbiological data and susceptibility
All blood, urine, and cerebrospinal cultures 
were prospectively reviewed for 4 months 
(November 1, 2002, to February 28, 2003) 
before the change from gentamicin to ami-
kacin treatment, and for 4 months (No-
vember 1, 2003, to February 29, 2004) af-
ter 8 months of amikacin use. Microbiologic 
data on the presence of GNB and their resis-
tance was recorded. Only aerobic GNB ob-
tained are reported. Copy strains were not 
included in the analysis. Antimicrobial sus-
ceptibilities were determined by Kirby-Bau-
er disk diffusion. Aminoglycoside resistance 
was confirmed periodically on randomly se-
lected isolates by minimum inhibitory con-
centration determination according to the 
National Committee for Clinical Labora-
tory Standards criteria (16). Gentamicin, 
amikacin, and netilmicin were the only ami-
noglycosides used in the routine antimicro-
bial susceptibility testing and aminoglyco-
side resistance could be transferable. Data 
on hospital length of stay from admission 
to bloodstream infection and the number of 
bloodstream infections were obtained from 
clinical charts by clinical pharmacologists in 
the previously described 4-month periods, in 
order to distinguish nosocomial from out-of-
hospital bloodstream infections. Nosocomial 
infections were defined as those isolated after 
48 hours of admission to ICU. During both 
periods, the methods of hospital infection 
control remained unchanged.
Antibiotic consumption
Consumption of antibiotics was recorded as 
the total weight of the drug in grams and then 
converted to the defined daily dose (DDD) 
per 100 patient-days, in accordance with the 
World Health Organization recommendation 
(17). The number of admissions and the num-
ber of days spent in the ICU were recorded for 
each ICU, both by the clinical pharmacologist 
visiting the ICU and from the hospital admin-
istrative data. Admission and discharge days 
were counted as one day.
Measurement of costs
The daily antibiotic costs per patient were cal-
culated in Euros, based on the prices of an-
timicrobial agents provided by the hospital 
pharmacy. The daily antibiotic cost per infect-
ed patient was calculated by the multiplication 
of price per package and the number of daily 
doses that was used for the treatment of infec-
tion. Because the major benefit of the prima-
ry amikacin usage was a reduction in the need 
for antimicrobial treatment, the primary end-
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point of the cost-saving analysis was the rise 
in the cost of antibiotic usage avoided by ami-
kacin treatment compared with gentamicin 
treatment. This cost-effectiveness ratio was cal-
culated by dividing the difference in mean dai-
ly amikacin and gentamicin costs per patient 
in the ICU by the difference in the total daily 
antibiotic costs per patient in the ICU in the 
two treatment periods.
Statistical analysis
Susceptibilities and frequencies of isolated 
bacteria obtained during the gentamicin pe-
riod were compared with the data from the 
amikacin period by z-test of proportions. 
Number of patients admitted to ICUs, sep-
sis rate, number of hospital acquired and 
out-hospital infections and antibiotic con-
sumption were compared by χ2 test. Aver-
age number of patient-days spent in ICU 
was compared by t-test. Software used for the 
analysis was the Statistical Package for the 
Social Sciences, version 10 (SPSS Inc., Chica-
go, IL, USA). The level of significance was set 
at P<0.05.
Results
Resistance to aminoglycosides
We tested 676 g-negative isolates from blood, 
urine, and cerebrospinal fluid of patients in 
ICUs against aminoglycosides in gentamicin 
and amikacin period. The overall gentamicin 
resistance of GNB decreased from 42% to 26% 
(P<0.001), netilmicin resistance decreased 
from 33% to 20% (P<0.010), whereas ami-
kacin resistance did not significantly change 
(from 20% to 19%; P = 0.462) in the amika-
cin period (Table 1). However, Escherichia coli 
and Pseudomonas aeruginosa showed a signifi-
cant reduction and Acinetobacter baumannii 
a significant increase of amikacin resistance in 
the amikacin period (Table 1). All GNB test-
ed showed significant reduction in gentamicin 
and netilmicin resistance during amikacin pe-
riod, except for Klebsiella pneumoniae and En-
terobacter, which showed a non-significant re-
duction (Table 1).
Incidence of bacteremia
P. aeruginosa was most frequently isolated 
GNB in both periods, followed by K. pneu-
moniae and A. baumannii in gentamicin peri-
od and K. pneumoniae, Enterobacter spp., and 
E coli in amikacin period (Table 2). The overall 
Table 1. Gram-negative bacteria (GNB) resistant to aminoglycosides (gentamicin, amikacin, and netilmicin) in intensive care units in 
gentamicin and amikacin period
No. (%) of resistant isolates in
gentamicin period amikacin period; P*
GNB* n† gentamicin amikacin netilmicin n† gentamicin P amikacin P netilmicin P
Proteus mirabilis  36  10 (28)  1 (2)   8 (22)  18  4 (22)  0.030  1 (6) >0.950  2 (11)  0.014
Enterobacter spp  31  13 (42)  6 (19)  10 (32)  26  8 (31)  0.157  3 (12)  0.317  7 (27)  0.083
Escherichia coli 123  37 (30) 32 (26)  31 (25)  75 10 (13) <0.001  5 (7) <0.001  4 (5) <0.001
Acinetobacter 
baumannii  34  25 (73)  6 (17)  16 (48)  24 14 (58)  0.001 14 (58)  0.014 10 (42)  0.014
Pseudomonas spp 122  59 (48) 45 (37)  51 (42)  62 23 (37) <0.001 11 (18) <0.001 22 (35) <0.001
Klebsiella spp  78  24 (31) 17 (22)  20 (26)  47  9 (19)  0.083  5 (11)  0.157  6 (13) <0.001
All GNB 424 178 (42) 85 (20) 140 (33) 252 66 (26) <0.001 48 (19)  0.456 50 (20) <0.001
*Gentamicin vs amikacin period, z-test of proportions.
†n – number of isolates.
Table 2. Gram-negative bacteria (GNB) in blood cultures taken 
from patients in intensive care units
No (%) of isolated bacteria 
in blood cultures in
 
GNB
gentamicin period 
(n = 142)†
amikacin period 
(n = 155)†
 
P*
Pseudomonas aeruginosa  9 (6.4)  9 (5.8) >0.950
Klebsiella pneumoniae  5 (3.5)  3 (1.9)  0.157
Acinetobacter spp.  5 (3.5)  2 (1.3)  0.083
Escherichia coli  3 (2.1)  3 (1.9) >0.950
Proteus mirabilis  2 (1.4)  0  0.157
Enterobacter spp.  0  3 (1.9)  0.083
Other  8 (5.6)  4 (2.6)  0.046
All GNB 32 (22.5) 24 (15.5)  0.005
*Gentamicin vs amikacin period, z-test of proportions.
†n – number of blood cultures.
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number of patients having GNB bloodstream 
infection was significantly reduced from 
15.4/1000 patient-days to 11.5/1000 patient-
days (P<0.001; z-test of proportions) during 
amikacin period, with the reduction of sepsis 
rate from 3.6% to 2.2% (P<0.001; χ2 test). The 
percentage of GNB in blood cultures taken 
from ICU patients was significantly reduced 
from 23% to 16% (P = 0.005) in the amikacin 
period. Hospital-acquired GNB bloodstream 
infections were significantly reduced from 
55/100 patient-days to 26/100 patient-days in 
the amikacin period (P = 0.001; χ2 test), while 
out-hospital bloodstream infections in ICUs 
remained unchanged, ie, dropped from 99/100 
patient-days to 89/100 patient-days. Frequen-
cies of P. aeruginosa and E. coli did not show 
significant difference in these two periods. En-
terobacter spp. was the only GNB that was iso-
lated more frequently during amikacin period. 
The remaining GNB were reduced with exclu-
sive use of amikacin (Table 2).
Antibiotic consumption
Overall antibiotic consumption was reduced 
from 92 DDD/100 patient-days in gentami-
cin period to 79 DDD/100 patient-days in 
amikacin period (P = 0.300) (Table 3). Ami-
kacin and gentamicin consumption showed 
significant changes between these two periods, 
while the consumption of other antimicrobi-
als remained unchanged. There were no dif-
ferences in the length of stay in the ICU be-
tween amikacin (average 2.364 days/patient) 
and gentamicin period (average 2.466 days/
patient; P = 0.757; t test)
Cost analysis
The mean increase in the initial treatment 
costs for amikacin instead of gentamicin was 
€0.14 per ICU patient daily, while resource 
utilization and related health care costs re-
mained unchanged. Use of amikacin was as-
sociated with 0.8% reduction in the total 
antibiotic costs, from €12.72/patient/d in 
gentamicin to €12.62/patient/d in amika-
cin period. In particular, total antibiotic costs 
were reduced by €0.1 per patient daily in ami-
kacin period, as compared with gentamicin pe-
riod. The incremental cost-effectiveness ratio 
for amikacin period was 1.4 (€0.14/patient/
d/€0.1/patient/d).
Discussion
We showed that exclusive usage of amika-
cin significantly reduced the resistance of 
GNB isolates to gentamicin and netilmicin, 
the number of GNB nosocomial bacteremi-
as, and the cost of total antibiotic usage in 
the ICUs. The primary mechanism of ami-
noglycoside resistance is through the activity 
of plasmid-mediated modifying enzymes (5). 
There are no effective clinical ways to inhib-
it these resistance enzymes (18) as there are 
ways to inhibit beta-lactamases. Since there 
is no effective strategy to directly interact 
with the mechanism of aminoglycoside re-
sistance, rational use of aminoglycosides is 
of utmost importance (19). Rotational us-
age practices are likely to be most appropri-
ate for drugs acting against GNB, because of 
Table 3. Number of patients, infections, antibiotic consumption, and cost in intensive care units (ICU)
Parameters Gentamicin period Amikacin period P
Number of patients admitted to ICUs 5706 6001 0.006*
Average number of patient-days spent in ICU (mean±standard deviation) 2.3 ± 0.5 2.5 ± 0.6 0.756†
Sepsis rate (%)    3.6    2.2 0.001*
Number of hospital acquired infections/100 patient-days   55   26 0.001*
Number of out-of-hospital infections/100 patient-days   99   89 0.466*
Antibiotic consumption (defined daily dose/100 patient-days)   92   79 0.300*
*χ2 test.
†t test.
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the wide choice of drugs available for rota-
tion (11). Antibiotic cycling is not associated 
with significant changes in the receipt of ap-
propriate empirical antimicrobial therapy for 
the treatment of ICU infections (20). In crit-
ically ill medical patients, a monthly rotation 
of anti-Pseudomonas beta-lactams and cipro-
floxacin is better than the strategy of mixing 
in the acquisition of P. aeruginosa resistant 
to selected beta-lactams (21). The optimal 
cost-effective rotational regimen for amino-
glycosides is yet to be explored (22). We have 
shown that a year of primary use of amikacin 
significantly reduced the resistance of GNB 
to gentamicin and netilmicin, without affect-
ing amikacin susceptibility. Although signif-
icant changes occurred over time, the over-
all rate of GNB resistant to aminoglycosides 
in Croatia remained high (23). Baršić et al 
(24) reported slightly higher resistance rates 
among GNB isolates in ICU in 2001, but the 
study was performed in the ICU of a hospital 
for infectious diseases. In a similar study, but 
with four antimicrobial agents and a focus 
on rectal swab cultures, cycling did not result 
in a significant change in enteric acquisition 
of resistant GNB among ICU patients (25). 
However, for cycling of two other antibiot-
ic classes, quinolones and beta-lactams, there 
was no control of the emergence of gram-neg-
ative antimicrobial resistance in ICUs (26).
More importantly, we have shown that 
amikacin treatment significantly reduced the 
number of GNB hospital infections in the 
ICU. By using amikacin rather than genta-
micin for treatment of infections, more bac-
teria were susceptible to antibiotic treatment 
and the ICU ecology was altered in such a 
way that fewer patients acquired nosocomi-
al GNB, reducing the overall number of in-
fections in ICUs. The overall drop in the in-
fection rates resulted also in a reduced sepsis 
rate. Results of this study are supported by 
other studies demonstrating improved sus-
ceptibility profiles of selected clinically im-
portant gram-negative ICU isolates after the 
initiation of the cycling protocol. We previ-
ously showed that ampicillin plus gentamicin, 
as empirical therapy of infection in a neona-
tal ICU, significantly reduce the number of 
cases of K. pneumoniae from the bacteremia 
and meningitis, as compared with ampicillin 
plus cefuroxime (27). We have also shown 
earlier that replacement of cefuroxime and 
gentamicin with ceftazidime and amikacin as 
empirical therapy lead to a significant reduc-
tion in the number of positive blood cultures 
and the number of bacteriologically verified 
septic episodes in neurosurgical ICU (28). 
In this study, the same trend of reduction of 
GNB from bactremia is observed when gen-
tamicin is replaced by amikacin. The 2-year 
duration of the study minimizes the poten-
tial impact of short-term confounding vari-
ables, such as concurrent outbreaks and lim-
ited clinical practice changes. During both 
periods, methods of the hospital infection 
control remained unchanged. Although we 
are unaware of any other concurrent chang-
es in the practice that would preferentially af-
fect the bacteremia, confounding variables, 
such as changes in the severity of illness and 
other antimicrobial usage patterns, cannot be 
excluded and could be possible limitations of 
the study. Variables like catheters, disinfec-
tion policies, or surgical techniques were not 
changed. However, we did not observe major 
changes in other infections in those ICU pa-
tients (data not shown) that would presum-
ably be influenced by the same confounding 
variables.
The reduction in the overall number of in-
fections in ICUs in amikacin period subse-
quently led to a reduced antibiotic consump-
tion. Though daily expenses per ICU patient 
were increased by €0.14 for amikacin instead 
of gentamicin use, total antibiotic costs were 
decreased by €0.1 per ICU patient daily. Cost 
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is an important factor which determines the 
physician’s choice of medication to treat pa-
tients in specific situations (29). Although the 
true cost of GNB infection is disputed, daily 
cost of antimicrobial treatment has been re-
ported to be a significant extra cost attribut-
able to infections (30).
The results collectively show that exclusive 
usage of amikacin significantly reduces the re-
sistance of GNB isolates to gentamicin and 
netilmicin and, more importantly, reduces the 
number of patients with GNB nosocomial in-
fections and overall cost of antimicrobial treat-
ment in ICUs.
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